engleski

Lymphocyte T response to Daclizumab's therapy in patient with renal transplantation

INTRODUCTION During last 25 years the number of patients with chronicle renal's insufficiency had increased. Most efficient treatment is kidney transplantation. Patients with transplanted kidney are in need of immunosuppressive treatment of graft rejection. Daclizumab (Zenapax®) is drug used in prevention of acute rejection of transplanted kidneys. It is human monoclonal antibody of IgG1 subclass, produced by recombinant DNA technology, which suppresses proliferation of lymphocytes. Using different concentration of Daclizumab we observed its affect on peripheral blood lymphocytes. METHODS We acquired periphery blood lymphocytes from 20 patients with transplanted kidneys. Part of each patient’s lymphocytes were stimulated in vitro by anti-CD3 antibodies, the rest was untreated. Afterwords the effect of Daclizumab on cell cycle (G0/G1 vs S/G2+M) of stimulated and non-stimulated lymphocytes was studied. Proliferative response was measured by analyzing the cell cycle of peripheral blood lymphocytes using flow citometry, in patient before and during 45-days treatment with Daclizumab. The control group was healthy blood donors. RESULTS We detected increased number of lymphocytes in G0/G1 phase and decreased number in S+(G2+M) phase compared to control group (P<0.01). Furthermore dose-dependent decreased proliferative response in anti-CD3 stimulated lymphocytes was observed. The results are concordant with recently published data. CONCLUSION Analyze of cell cycle showed decreased proliferative capacity of lymphocytes in patients treated with Daclizumab in comparison to control group. Flow cytometry proves to be non invasive, cheap, relatively simple and reliable method for analyzing the level of immunosupresion.

Daclizumab; Flow Cytometry; Immunosuppression; Cell Cycle Analysis; Lymphocyte Immunophenotyping; Renal Transplantation

nije evidentirano